J Korean Soc Spine Surg.  2014 Dec;21(4):194-199. 10.4184/jkss.2014.21.4.194.

Customized Treatment for the Prevention of Osteoporotic Fracture

• Park YS
• Park JS

• KMID: 2097872
• DOI: http://doi.org/10.4184/jkss.2014.21.4.194

Abstract

STUDY DESIGN: A review of related literature regarding the prevention of osteoporotic fractures.
OBJECTIVES
To discuss the customized treatment and prevention of osteoporotic fracture. SUMMARY OF LITERATURE REVIEW: Various customized treatments for osteoporosis have been discussed.
MATERIALS AND METHODS
Review of related literatures.
RESULTS
It would be best to individualize medications based on each patient's sex, age, bone density in the spine and hip bones, presence or absence of drug over-use for underlying comorbidities, presence or absence of a gastrointestinal disease, duration of bisphosphonate usage, and presence or absence of an adverse effect, and drug efficacy according to the analysis of follow-up bone density, and compliance.
CONCLUSIONS
Pharmacotherapy should be combined with various prophylactic therapies to prevent osteoporotic fractures. Various factors should be considered as well before selecting an osteoporosis medication. Different types of medications may have different effects in their ability to reduce fracture risk in patient with different bone densities and other characteristics.

Keyword

Customized treatment; Prevention; Osteoporotic fracture

MeSH Terms

Bone Density
Comorbidity
Compliance
Drug Therapy
Follow-Up Studies
Gastrointestinal Diseases
Hip
Humans
Osteoporosis
Osteoporotic Fractures*
Spine

Reference

1. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhi-bition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin In-vest. 1998; 102:274–82.

2. Park YS. Diagnosis and treatment of osteoporosis. J Korean Med Assoc. 2012; 55:1083–94.

3. Watts NB, Bilezikian JP, Camacho PM, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 2010; 16(3 Suppl):1–37.

4. Fleisch HA. Bisphosphonates: preclinical aspects and use in osteoporosis. Ann Med. 1997; 29:55–62.

5. Lee JH, Lee JW, Seo WS, Park YS. Analysis of Adherence of Once-yearly Intravenous Zolendronic Acid for Osteoporosis. Osteoporosis. 2014; 12:22–9.

6. Bone HG, Hosking D, Devoglelaer JP. Ten years’ experince with Alendronate for Osteoporosis in Postmenopausal Women. N Engl J Med. 2004; 350:1189–99.

7. McClung MR, Geusens P, Miller PD, et al. Effect of rise-dronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001; 344:333–40.

8. S⊘ rensen HT, Christensen S, Mehnert F, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ. 2008; 336:813–6.

9. Hong JW, Nam W, Cha IH, et al. Oral bisphosphonate-related osteonecrosis of the first report in Asia. Osteoporos Int. 2010; 21:847–53.

10. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-Associat-ed Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22:1479–91.

11. Lee YK, Ha YC, Choi HJ, et al. Bisphosphonate use and subsequent hip fracture in South Korea. Osteoporos Int. 2013; 24:2887–92.

12. Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res. 2009; 24:1095–102.

13. Das De S, Setiobudi T, Shen L, Das De S. A rational approach to management of alendronate-related subtrochanteric frac¬tures. J Bone Joint Surg Br. 2010; 92:679–86.

14. Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the american society for bone and mineral research. J Bone Miner Res. 2014; 29:1–23.

15. McClung MR, Miller PD, Brown JP, et al. Efficacy and safety of a novel delayed-release risedronate35 mg once-a-week tablet. Osteoporos Int. 2012; 23:267–76.

16. Hodges LA, Connollya SM, Winterb J, at al. Modulation of gastric pH by a buffered soluble effervescent formulation: A possible means of improving gastric tolerability of alendronate. Int J Pharm. 2012; 432:57–62.

17. Boyd JJ, Gaich GA, Scheele WH, et al. A randomized double-blind trial to compare the efficacy of teriparatide[recombinant human parathyroid hormone I-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002; 87:4528–35.

18. Watts NB, Diab DL. Longterm use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010; 95:1555–65.

19. McClung M, Harris ST, Miller PD, et al. Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holi-day. AM J Med. 2013; 126:13–20.